Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Cytarabine + Thalidomide in Untreated Adult LCH
NCT07187193Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, thalidomide in Langerhans cell histiocytosis (LCH), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Apr 2025; status: recruiting.
02
Drugs
cytarabinethalidomide
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT07187193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187193.